3/10 · Low — a mature, cyclical regional bank; growth is real but acquisition-fueled and decelerating to a mid-single-digit organic base
Technicals
Mild uptrend — $17.86, −7% off 52-wk high, just above 50/200-DMA, RSI 60, +4% 12-mo (SPY +21%) — a laggard vs the market
Conviction
Low — 0 expert voices in the Synthos KB; the call rests entirely on fundamentals + quant
Position sizing
Income/value satellite, ~1–3% if bought — not a core conviction holding
Next catalyst
2026-07-23 Q2'26 earnings (Street EPS $0.39)
Single biggest risk
Credit cycle + integration: two large 2025–26 acquisitions (Veritex, Cadence) mid-integration into an uncertain-economy loan book
One-line thesis. Huntington is a cheap (13× earnings, ~book value), low-beta super-regional bank that just doubled its Texas/South footprint through the Veritex and Cadence acquisitions — the numbers are solid (NIM rising to 3.24%, NCOs low at 0.26%, CET1 10.2%) but the growth is bought, not organic, ROA is still under 1%, and with zero expert coverage and a cyclical setup the honest call is Watch, not a table-pounding buy.
◆ Synthos call — Buy — TacticalHBAN offers ~12% upside to fair value (~$20) with the trend confirming — buy $17–$18, take profits toward $20, and exit on a close below the 200-day (~$17).
Downside Risk (lower = safer)
5/10 · Moderate
Cheap (13× EPS, ~1.0× book) & low beta (0.97), but cyclical, rate-sensitive, and mid-integration on two acquisitions.
Growth Quality
5/10 · Moderate
~15% FY25→28E EPS CAGR is acquisition-fueled, not organic; ROA still <1%, ROTCE depressed by deal costs.
Exponential Potential
3/10 · Low
A ~$36B regional bank in a mature, cyclical industry — steady compounder at best, not an exponential.
◆ Target entry zone$17 – $18accumulate in this band; ideal adds on a dip toward the 200-day average near $17, keeping roughly a 11% margin below our $20 base-case fair value⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 8%/yrTo justify today’s $18, earnings would have to compound roughly 8% a year for 10 years (9% discount rate). Analysts forecast ~3%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Huntington is a big regional bank based in Columbus, Ohio — checking accounts, mortgages, car loans, and business lending across the Midwest, and now Texas and the South after two big 2025–26 takeovers. Think of it as a solid, boring bank, not a tech rocket.
Is the stock cheap or expensive? Cheap-ish. You're paying about $13 for every $1 the bank earns in a year, and roughly the value of the bank's own net worth — banks this profitable often cost more. It also pays you about 3.5% a year in dividends just to hold it.
Our verdict is Watch — meaning: nice bank, fair price, but there's no rush. Two reasons to wait: (1) the bank just swallowed two other banks and is still digesting them, and blending computer systems and loan books can throw off surprises; (2) banks make or lose money with the economy, and if loans go bad in a downturn, profits shrink fast.
Here's what our three scores mean in everyday terms:
Downside Risk 5/10 (middle of the road). It's cheap and doesn't swing wildly, which is safe — but it's a bank, so a recession or a bad-loan surprise would hurt.
Growth Quality 5/10 (average). It's growing, but mostly because it bought other banks, not because the core business is booming.
Exponential Potential 3/10 (low). This is a steady, mature company. Don't expect it to double quickly — expect dividends and slow, steady gains.
The one big worry: the bank is mid-way through combining two acquisitions right as the economy looks shaky, and if loans start going bad the profits (and the stock) would take a hit.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = HBAN · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$17.86
Market cap$36B
P/E trailing1×
P/E FY26E / FY27E12× / 9×
EV / Sales4.3×
EV / EBITDA17.7×
Gross margin62.6%
Net margin16.6%
Dividend yield3.47%
Beta0.969
52-wk range$15 – $19
RSI(14)60
50 / 200-DMA$17 / $17
12-mo return+4% (SPY +21%)
Street target$20 ($18–$21)
Analyst grades24 Buy · 20 Hold · 3 Sell
FMP ratingB+
Next earnings2026-08-05
What the experts actually said 0 traceable claims on HBAN · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Huntington Bancshares (NASDAQ: HBAN) is the bank holding company for The Huntington National Bank, founded in Columbus, Ohio, in 1866. It is a super-regional bank — roughly $225B in total assets as of year-end 2025 — organized into four segments: Consumer & Business Banking (checking, savings, cards, mortgages for individuals and small businesses); Commercial Banking (middle-market, commercial real estate, and specialty verticals like healthcare, technology, and sponsor finance); Vehicle Finance (auto, RV, and marine lending through dealers); and Regional Banking / Huntington Private Client Group (private banking, wealth and investment management). CEO Stephen D. Steinour. Fiscal year ends December 31; ~20,000 employees.
The story of the last 18 months is M&A-driven scale expansion into Texas and the South: Huntington completed the Veritex Holdings acquisition (systems conversion mid-January 2026) and closed the Cadence Bank partnership on February 1, 2026 (integration expected complete in Q2 2026). Together these vaulted average loans to $174.2B (+33% YoY) and average deposits to $204.6B (+27% YoY) in Q1'26.
Revenue mix. As a bank, the meaningful cut is net interest income vs. noninterest (fee) income, not the FMP product segmentation. In Q1'26 (per the earnings release): net interest income $1,891M (+33% YoY) plus noninterest income $682M (+38% YoY) for total revenue-FTE $2,592M (+34% YoY). The FMP fee-line segmentation (FY2025) shows the fee mix: cards & payment processing $613M, trust & investment management $408M, service charges $250M, insurance $81M — a diversified fee base on top of spread income. (FMP reports no geographic segmentation for HBAN; the footprint spans 11+ states plus the new Texas/South territory.)
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage for HBAN in the Synthos knowledge base.total_claims = 0; there are zero net-bullish (or bearish) voices and zero traceable claim_ids. This is a quant/screen-track name, not a conviction name.
What that means for this note: every judgment below is derived from the reported financials (FMP filings), live analyst estimates, management's own SEC 8-K earnings release, and Synthos's quantitative scoring — not from any distilled expert conviction. We will not manufacture a thesis we cannot cite. Where we reference outside opinion, it is the sell-side Street consensus (25 Buy-leaning / 20 Hold / 3 Sell, PT $20.40) and management's self-interested commentary (§9), both explicitly labeled and neither used as our anchor.
For context, the closest thing to third-party validation is the FMP letter rating of B+ (overall score 3/5, with the best marks on DCF and price-to-book, weakest on debt-to-equity) — a middling-to-solid quantitative grade, consistent with our own read.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
5 · Moderate
Cheap (13.4× EPS, ~1.0× book) and low beta (0.97) with a 3.5% yield cushion — but it's a cyclical, rate-sensitive bank mid-integration on two acquisitions, with ROA still <1% and CET1 a merely-adequate 10.2%.
Growth Quality
5 · Average
~15% FY25→FY28E EPS CAGR looks good, but it is acquisition-fueled (loans +33% YoY came from Cadence/Veritex, not organic demand); ROTCE is depressed by deal costs and ROA is sub-1%. Solid, not special.
Exponential Potential
3 · Low
A ~$36B regional bank in a mature, consolidating, cyclical industry. Steady dividend compounder at best; the acceleration is a one-time M&A step-up, not a durable second-derivative story.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Cadence/Veritex synergies fully land; NIM holds ~3.3%+; credit stays benign; buyback ($3B authorization) shrinks the share count. FY27E EPS beats to ~$2.10; the market pays a ~12× premium-regional multiple.
~$25 (+40%)
Base(our anchor)
Deals integrate roughly on plan; EPS reaches Street's FY27E ~$1.91; a well-run but cyclical regional earns a ~10.5× forward multiple.
~$20 (+12%)
Bear
A credit cycle turns (CRE and commercial loan losses rise), NIM compresses, or integration stumbles. FY27E EPS misses to ~$1.55; multiple de-rates to ~8.5× on recession fear.
~$13 (−27%)
Synthos fair value = the base case, ~$20 (+12%), with the full $13–$25 span as the honest range. This anchor sits essentially on top of the Street's $20.40 consensus — an unusual case where our independent model and the sell-side agree the stock is roughly fairly valued with modest upside. That agreement, plus the absence of any differentiated expert edge, is precisely why the verdict is Watch rather than Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). HBAN is neither an exponential nor even an elite compounder — it is a steady, cyclical regional bank:
Forward growth: EPS CAGR FY25→FY28E ~15.3% ($1.39 → $2.13 diluted). But revenue estimates actually step down in the out-years as FMP consensus normalizes the acquisition boost (FY26E rev avg $11.3B, FY27E $12.3B, FY28E $13.0B, then a thin/unreliable 1-analyst FY29 mark) — the growth is front-loaded by M&A, not a compounding organic engine.
Acceleration (the 2nd derivative) is a one-time step, not a trend: the +33% YoY loan growth and +34% revenue growth in Q1'26 are almost entirely the Cadence + Veritex acquisitions landing in the numbers. Strip those out and organic growth is mid-single-digit. Once the deals are lapped, the second derivative goes flat-to-negative. Per our flagship philosophy we hunt forward next-exponentials with accelerating organic growth — HBAN is the opposite: a mature name whose acceleration is bought and temporary.
Room to run: at $36B market cap in a ~$20T+ US banking system there is technically size headroom, but the industry is mature, commoditized, and consolidating — the binding constraint isn't TAM, it's that spread lending is a low-return, capital-intensive, cyclical business. A regional bank doesn't 5× on demand; it grinds out book-value + dividends.
Reinvestment runway: capital is being returned (a new $3B buyback authorization, ~$0.62/yr dividend) rather than plowed into hyper-growth — the correct move for this ROIC, but the tell of a compounder, not an exponential.
Exponential Potential: Low (3/10). Own HBAN, if at all, for a ~3.5% dividend + slow book-value compounding + a possible re-rating as the deals prove out — not for a multibagger. This honest framing is why HBAN sits in the income/value satellite bucket, not the flagship growth sleeve.
Revenue (FMP gross basis): FY25 $12.49B, +4.4% (FY24 $11.96B). On the bank's own total-revenue-FTE basis, Q1'26 was $2,592M, +34% YoY — the acquisition step-up.
Net interest income & margin: Q1'26 NII $1,891M, +19% QoQ / +33% YoY; net interest margin 3.24%, up from 3.10% a year ago and rising sequentially — a genuine positive (asset repricing + deal mix).
Earnings: FY25 net income $2,211M, EPS diluted $1.39. Q1'26 GAAP net income $523M ($0.25 EPS) was depressed by $271M of pre-tax acquisition-related Notable Items; management's adjusted EPS was $0.37 (non-GAAP, management's own figure — see §9).
Profitability: Q1'26 ROA 0.81%, ROE 7.2%, ROTCE 11.6% — all GAAP-depressed by deal costs (adjusted ROTCE runs higher). TTM ROE ~8.8%, ROA sub-1% — middling for the sector, a key reason growth quality is only average.
Credit (the thing that matters for a bank): net charge-offs 0.26% of average loans (low/benign), nonperforming-asset ratio 0.72%, allowance for credit losses 1.78% of loans ($3.4B) — solid credit metrics today, but a cyclical variable to watch.
Capital:CET1 10.2% (down from 10.4% as the acquisitions consumed capital), TCE ratio 7.0%, tangible book value per share $9.55. Capital is adequate, not fortress.
Cash flow: FY25 operating cash flow $2.55B, FCF $2.28B — bank cash flow is less meaningful than capital ratios, but it comfortably funds the dividend (~$1.0B/yr).
6. Valuation — priced in or room?
HBAN is genuinely inexpensive on earnings and book:13.4× trailing EPS, and on live consensus 12.0× FY26E → 9.4× FY27E as the acquisition earnings fully phase in. Price-to-book is ~1.0× (FMP P/B 1.03×; note tangible book of $9.55 vs. an $17.86 price reflects the large goodwill from the deals). Dividend yield is ~3.5%. For a bank posting a rising NIM and low charge-offs, none of that is expensive — it's the classic "cheap for a reason" regional-bank profile, where the discount reflects cyclicality and sub-1% ROA rather than mispricing.
The bull case is that as Cadence/Veritex synergies land and deal costs roll off, normalized EPS (~$1.90–$2.10) on even a 10–12× multiple supports low-$20s — and the $3B buyback accelerates per-share value. The bear case is that a credit cycle turns the cheap multiple into a value trap. Street targets (context): consensus $20.40, high $21, low $18 — our ~$20 base fair value lands right in the middle. Not a screaming bargain, not overpriced; fairly valued with modest upside, which is a Watch, not a Buy.
7. Technicals (from the tech block)
Trend:mildly up. $17.86 sits above the 50-DMA ($16.58) and 200-DMA ($16.72), with the 50 fractionally above the 200 — a shallow uptrend, not a powerful one.
Location:−7.3% off the 52-week high ($19.27), +18.9% off the 52-week low ($15.02); max drawdown from peak only −7.3% — well-behaved, no crash.
Momentum: RSI(14) 60 — firm but not overbought (<70). MACD +0.42 (mildly positive).
Relative strength (the tell): HBAN +4.0% 12-mo vs SPY +20.6% and QQQ +30.3% — a clear laggard over the past year. It has kept pace over 3 months (+12.5% vs SPY +13.7%) but trailed badly over 6–12 months. Financials-sector rotation, not company-specific breakdown.
Read: technicals are neutral-to-mildly-constructive — a stable, low-drama chart in a shallow uptrend, but with no momentum leadership. No technical urgency in either direction; consistent with a Watch.
8. Moat & competitive position
Bank "moats" are shallow and mostly local: HBAN's edge is a low-cost, sticky deposit franchise in the Midwest, a differentiated super-regional model (national commercial capabilities delivered with local relationship banking), and now expanded scale and geography in Texas and the South via Cadence/Veritex. Scale matters in banking (efficiency, tech spend, regulatory cost absorption), and Huntington's efficiency ratio (67.2% in Q1'26, elevated by deal costs; ~57–59% underlying) is respectable. But there is no durable pricing power — deposits and loans are commodities, and the business is fundamentally cyclical and rate-dependent. The competitive threat set is other super-regionals, money-center banks, and fintech deposit/lending disruption.
Peer set (market cap): U.S. Bancorp $95.8B, Truist $63.5B, Citizens Financial (CFG) $30.0B, Regions Financial (RF) $25.8B, KeyCorp (KEY) $24.8B, First Citizens (FCNCA) $24.1B, Shinhan Financial (SHG) $31.6B. Within the super-regional cohort HBAN is mid-pack on size and valuation — cheaper than USB/TFC on some measures, comparable to CFG/RF/KEY. No peer commands a wide multiple premium; the group re-rates together with rates and the credit cycle.
9. Management, capital allocation & guidance
Capital allocation: balanced and shareholder-friendly. A new $3B share-repurchase authorization (approved 2026-04-22, replacing the prior one), ~13M shares already bought back YTD, and a steady $0.155/quarter ($0.62/yr) dividend (~3.5% yield, ~48% payout). Capital was deployed into two sizable acquisitions — appropriate use if synergies land, dilutive to capital ratios (CET1 slipped to 10.2%) if they don't.
Insider activity: a mixed, non-alarming picture. Recent Form 4s show routine officer/director sales (General Counsel Hingst sold 10,568 shares at $18 on 2026-06-25; director Rollins sold 223,522 common shares at $17.35 on 2026-06-12) and director Rollins buying preferred stock (Series H and L deposit shares, early June 2026). No cluster of alarming discretionary common-stock selling; the largest activity is routine.
Management's own guidance (half-weighted — they talk their book): the SEC 8-K (Q1'26 earnings release, filed 2026-04-23) is a real earnings release and reads as management's self-interested framing. CEO Steve Steinour: "Coming off a transformational year in 2025, Huntington delivered a strong start to 2026 through disciplined execution and continued organic growth… our credit remains strong, and we are driving toward our committed expense and revenue synergies from our Veritex and Cadence partnerships… we are on schedule for a Cadence conversion in June. Both partnerships are already delivering growth opportunities across Texas and the South, and we expect further growth for years to come." Management explicitly guides to committed cost and revenue synergies from the two deals and a completed Cadence integration in Q2 2026, and frames the "strong balance sheet and industry-leading liquidity and reserves" as a source of strength amid "relative economic uncertainty." Treat this as directional and self-interested (half-weight): it confirms the integration timeline and synergy thesis but is not independent validation. No precise numeric full-year EPS/revenue guidance range was provided in the release.
10. Catalysts & what to watch
Next earnings: 2026-07-23 (Q2'26; Street EPS $0.39, revenue ~$2.84B). The key lines: whether the Cadence conversion (completed Q2) delivers the promised synergies, GAAP EPS clearing acquisition costs, and NIM direction.
Integration proof: cost and revenue synergies from Veritex/Cadence actually showing up in the efficiency ratio and adjusted EPS — the single biggest swing factor for the base case.
Credit trajectory: net charge-offs (0.26% now), NAL ratio (0.72%), and allowance coverage — the earliest warning if the cycle turns. Commercial-real-estate exposure specifically.
NIM & rates: whether the 3.24% margin holds as deposit costs and the rate environment move.
Buyback pace: execution against the $3B authorization shrinking the share count.
Thesis tripwires (what would change the call): a jump in net charge-offs or nonperforming assets (credit cycle turning); synergy shortfall or a botched Cadence conversion; NIM compression below ~3.0%; or CET1 slipping below ~10% without a clear rebuild path.
11. Key risks
Credit cycle (structural, #1): a bank's earnings live and die with loan losses. NCOs are benign today (0.26%) but a recession — into a freshly enlarged, acquisition-heavy loan book — is the core downside.
Integration risk: two large acquisitions (Veritex, Cadence) mid-integration; systems conversions and culture blends can produce surprises, and the synergies are promised, not banked.
Cyclicality & rate sensitivity: NIM, loan demand, and credit costs all swing with the macro/rate environment — outside management's control.
Capital adequacy: CET1 at 10.2% is adequate, not fortress; the deals consumed capital, leaving less cushion for a shock.
No differentiated edge / no expert coverage: with zero KB conviction and a fair-value that matches consensus, there is no informational or valuation edge here — the market already prices HBAN roughly correctly.
12. Verdict, position sizing & monitoring
Watch. Huntington is a genuinely well-run, cheap (13× earnings, ~book value, 3.5% yield), low-beta super-regional bank with a rising NIM, benign credit, and a credible M&A-driven expansion into Texas and the South. But three things keep it off the buy list: (1) the growth is bought, not organic — ROA is still sub-1% and the acceleration is a one-time acquisition step-up; (2) it's mid-integration on two deals into an uncertain economy, which is exactly when regional-bank surprises happen; and (3) there is no expert conviction and no valuation edge — our independent fair value (~$20) sits right on the Street's $20.40, so the market already prices it fairly. That combination is the textbook definition of a Watch: nothing wrong, nothing compelling.
Sizing:if an investor wants regional-bank/income exposure, HBAN is a reasonable ~1–3% income/value satellite — not a core conviction position. The best entry would be after the Cadence integration proves out (post-Q2/Q3'26 prints) or on a credit-fear pullback toward tangible book.
Monitoring: re-underwrite on the tripwires in §10; formal re-score each earnings print, with special attention to charge-offs and synergy realization. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $17.86.
Single biggest risk: the credit cycle turning into a freshly enlarged, acquisition-heavy loan book while integration is still underway.
Provenance & disclosures
Traceability:0 KB claims — no expert coverage in the Synthos knowledge base for HBAN. This note is fundamentals- and quant-driven; no conviction is claimed and none is fabricated (claim-ID reconciliation makes fabricated conviction structurally impossible).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from SEC 8-K filed 2026-04-23. Forward figures are analyst consensus (FMP) or our own scenario model, labeled as estimates.
Management caveat: CEO commentary and adjusted (non-GAAP) figures in §9 are management's own, self-interested framing, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").